Lineage Cell Therapeutics Inc. has announced a change in its independent registered public accounting firm following the merger of its current auditor, Moss Adams LLP, with Baker Tilly US, LLP. Effective June 3, 2025, Moss Adams resigned as the company's auditor, and the Audit Committee of Lineage Cell Therapeutics' Board of Directors has appointed Baker Tilly as the new independent registered public accounting firm for the fiscal year ending December 31, 2025. This transition comes after Moss Adams had been the appointed auditor since June 2024. The company confirmed that there were no disagreements or reportable events that required disclosure during this transition period. A formal letter from Moss Adams confirming their agreement with the company's statements has been filed with the U.S. Securities and Exchange Commission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.